PMG
AMAG

ProVise Management Group’s AMAG Pharmaceuticals AMAG Stock Holding History

ProVise Management Group’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-11,300
Closed -$277K – 352
2016
Q3 		$277K Buy
+11,300
New +$282K 0.05% 270

Other funds holding AMAG

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProVise Management Group's AMAG Position: Q4 2016 in Review

ProVise Management Group sold out of AMAG Pharmaceuticals (AMAG) in Q4 2016, closing a stake of 11,300 shares — an estimated $277K sold.

ProVise Management Group first reported a position in AMAG in Q3 2016 and held it in 1 quarter. The position peaked at $277K in Q3 2016. 206 funds tracked by Wall St. Rank hold AMAG as of Q4 2016.

  • ProVise Management Group reported no remaining AMAG Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • ProVise Management Group sold 11,300 AMAG Pharmaceuticals shares in Q4 2016, an estimated $277K.
  • ProVise Management Group first reported a position in AMAG Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • ProVise Management Group's AMAG Pharmaceuticals position peaked at $277K in Q3 2016.
  • 206 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2016.

Based on ProVise Management Group's 13F filing for Q4 2016, filed 8 Feb 2017.